Michael C Singer1, Francis Marchal2, Peter Angelos3, Vic Bernet4, Laura Boucai5, Samanta Buchholzer6, Brian Burkey7, David Eisele8, Evren Erkul9, Frederic Faure2, Suzanne K Freitag10, Marion Boyd Gillespie11, Richard Mack Harrell12, Dana Hartl13, Megan Haymart14, Jonathan Leffert15, Susan Mandel16, Barbra S Miller17, John Morris18, Elizabeth N Pearce19, Rahmatullah Rahmati20, William R Ryan21, Barry Schaitkin22, Martin Schlumberger23, Brendan C Stack24, Doug Van Nostrand25, Ka Kit Wong26, Gregory Randolph27. 1. Department of Otolaryngology - Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan, USA. 2. Department of Otolaryngology - Head and Neck Surgery, Geneva University Hospital, Geneva, Switzerland. 3. Department of Surgery, University of Chicago Medical Center, Chicago, Illinois, USA. 4. Department of Endocrinology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA. 5. Department of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 6. Maxillofacial Surgery and Oral Medicine and Pathology, Geneva University Hospital, Geneva, Switzerland. 7. Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, USA. 8. Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 9. Department of Otorhinolaryngology, Gulhane Medical School, University of Health Sciences, Istanbul, Turkey. 10. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA. 11. Department of Otolaryngology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA. 12. Memorial Center for Integrative Endocrine Surgery, Memorial Healthcare System, Hollywood, Florida, USA. 13. Department of Head and Neck Oncology, Institut de Cancerologie Gustave Roussy, Villejuif, France. 14. Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA. 15. North Texas Endocrine Center, Dallas, Texas, USA. 16. Department of Endocrinology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 17. Division of Endocrine Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA. 18. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA. 19. Department of Medicine, Section of Endocrinology, Diabetes, Nutrition & Weight Management, Boston University School of Medicine, Boston, Massachusetts, USA. 20. Division of Otolaryngology, Yale School of Medicine, New Haven, Connecticut, USA. 21. Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, California, USA. 22. Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 23. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris-Saclay, Villejuif, France. 24. Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, Illinois, USA. 25. Division of Nuclear Medicine, MedStar Washington Hospital Center, Washington, District of Columbia, USA. 26. Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, Michigan, USA. 27. Department of Otolaryngology - Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Postoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement. METHODS: A multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations. RESULTS: Consensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management. CONCLUSION: Salivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
BACKGROUND: Postoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement. METHODS: A multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations. RESULTS: Consensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management. CONCLUSION: Salivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
Authors: G Y Yu; D G Liu; W Li; X Hong; Y Y Zhang; W X Zhu; K F Zhang; X Li; Z G Li; Y Y Liu; Y Chen; Y Gao; J Z Su Journal: Beijing Da Xue Xue Bao Yi Xue Ban Date: 2022-02-18
Authors: Vikas Mehta; Ankita Naraparaju; David Liao; Louise Davies; Bryan R Haugen; Peter A Kopp; Susan J Mandel; Yuri E Nikiforov; Douglas S Ross; Jennifer J Shin; R Michael Tuttle; Gregory W Randolph Journal: Thyroid Date: 2022-01-07 Impact factor: 6.506
Authors: Lauren P Wallner; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Carrie Lubitz; Sarah T Hawley; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958